tbuckley/cabot-search huggingface dataset:
Adjuvant chemotherapy followed by adjuvant radiotherapy for treatment of high risk endometrial cancers: A retrospective review.
Authors: Anjali Kulkarni, Tien Le, Ege Babadagli, Rajiv Samant
Journal: Journal of Clinical Oncology (2022)

e17626 Background: Endometrial cancer is the most common gynecologic malignancy in North America (1-3). Patients who are considered to be high risk for recurrence are commonly treated with a combination of adjuvant chemotherapy and radiation. However, the optimal sequence of these therapies has not been defined. The purpose of this study is to review our progression-free survival (PFS) outcomes and recurrence rates and compare to established outcomes in the literature. Methods: A retrospective chart review was performed on all patients diagnosed with endometrial cancer who received adjuvant chemotherapy and radiation between Jan. 1, 2005 to Dec. 31, 2017 at The Ottawa Hospital. Main inclusion criteria for the study were stage III endometrial cancers of any histology, stage I-II endometrial cancers with serous or clear cell histology and stage IV endometrioid adenocarcinomas of the endometrium. The primary outcome of interest is the overall progression-free survival (PFS), defined as the time from surgery to disease recurrence or death by any cause. Results: A total of 140 patients were included in the study. Of these, 52 (37.1%) had endometrioid histology, 75 (53.6%) had serous, and 11 (7.9%) had clear cell histology. Of the total sample, 41 (29.3%) were stage 1 at diagnosis, 24 (17.1%) were stage 2, 68 (48.6%) were stage 3 and 7 (5.0%) were stage 4. The median start time to chemotherapy was 49 days after initial surgery. 130 (92.9%) completed a total of 6 cycles of chemotherapy (majority treated with carboplatin and paclitaxel). 92% of the patients completed radiation following chemotherapy; majority received external beam radiation +/- a brachytherapy boost. Radiation was started withing 4-6 weeks of completing chemotherapy. 42 (30.0%) patients were diagnosed with a recurrence during the time of follow-up and 7 were diagnosed with progressive disease on treatment. Of the recurrences, 2 (4.8%) were local, 5 (11.9%) were locoregional, 8 (19.0%) were isolated para-aortic, and 27 (64.3%) were distant. The median follow-up time for our sample was 63.9 months. The median PFS and overall survival for our sample was not reached. The estimated mean 5 year PFS was 0.69 and OS was 0.66. Conclusions: Although radiation prevents locoregional recurrences, chemotherapy improves survival outcomes in locally advanced and aggressive histology endometrial cancer. Previous reported outcomes have been based on giving adjuvant radiation first, followed by chemotherapy (4,5). Our results demonstrate that giving adjuvant chemotherapy first and then delivering radiation after may be the optimal approach since it leads to survival outcomes that compare favourably with the published literature and very few locoregional relapses.
Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.
Authors: Swetha Kambhampati, Monica Saumoy, Stacy Pak, L Elizabeth Budde, Matthew Genyeh Mei, Leslie Popplewell, Yi-Ping Wen, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alex Francisco Herrera, Nikhil Thiruvengadam
Journal: Journal of Clinical Oncology (2022)

7568 Background: In patients with treatment naive diffuse large B-cell lymphoma (DLBCL), the POLARIX study demonstrated a 6.5% improvement in the 2-year (yr) progression-free survival (PFS) with no difference in overall survival or safety using polatuzumab vedotin + R-CHP compared to standard RCHOP. We evaluated the cost effectiveness of pola-R-CHP for DLBCL. Methods: We modeled a hypothetical cohort of US adults (mean age, 58 yrs) with treatment naïve DLBCL by developing a Markov model with a 1-month cycle and 20-yr horizon. The cost-effectiveness of two strategies were directly compared (pola-R-CHP, RCHOP) using a range of plausible long-term outcomes. A patient with DLBCL in remission after treatment could develop subsequent progression or relapse, death, or alternative toxicity. Progression rates and overall survival were estimated from POLARIX study. Outcome measures were reported in incremental cost-effectiveness ratios (ICERs), with a willingness-to-pay (WTP) threshold of $150,000/quality-adjusted life-yr (QALY). Results: Assuming a 5-yr PFS of 69.6% with pola-R-CHP and 62.6% with RCHOP, pola-R-CHP was more effective (0.81 incremental QALYs) but more costly ($66,218) and was cost-effective at a WTP of 150,000 (ICER $82,220/QALY). Its cost effectiveness was highly dependent on the 5-yr PFS of pola-R-CHP with it no longer being cost effective if the 5-yr PFS was &lt; 65%. One way sensitivity analysis demonstrated that pola-R-CHP is cost effective up to a cost of $270,506 at a WTP of $150,000. Probabilistic sensitivity analysis was derived from performing 10,000 Monte-Carlo model iterations and demonstrated that pola-R-CHP was the cost-effective strategy in 61.3% of iterations with RCHOP being cost-effective in 38.6% of iterations at a WTP of $150,000. Conclusions: If the absolute benefit in PFS is maintained over time, frontline pola-R-CHP for treatment of DLBCL would be cost effective at its current cost when compared to RCHOP at a WTP of $150,000/QALY. However, its cost effectiveness is highly sensitive to changes in long-term PFS and the cost of pola-R-CHP. If pola-R-CHP is adopted as frontline therapy for the 29,108 incident cases of DLBCL annually in the US, this will lead to an additional 1.8 billion dollars in healthcare expenditures. This highlights the importance of decreasing the cost of pola-R-CHP and identifying sub-populations that derive the highest benefit from it.[Table: see text]
Compared Efficacy of Adjuvant Intravesical BCG TICE vs. RIVM for High-risk Non-muscle Invasive Bladder Cancer: A Multicenter Propensity Score Matched Analysis
Authors: F. Del Giudice, S. Flammia, A. Sciarra, S. Salciccia, M. Maggi, V. Canale, P. Viscuso, M. Moriconi, G.M. Busetto, U. Falagario, G. Carrieri, L. Cormio, E.C. Skinner, B.I. Chung, E. De Berardinis
Journal: European Urology (2022)
Laparoscopic versus robotic partial nephrectomy in obese patients: Perioperative and early functional outcomes from a large contemporary series (RECORD2 project)
Authors: R. Tellini, A. Mari, A. Antonelli, L. Lambertini, P. Bove, E. Brunocilla, U. Capitanio, E. Checcucci, F. Di Maida, P. Gontero, N. Longo, F. Montorsi, F. Porpiglia, A. Porreca, B. Rocco, R. Schiavina, S. Serni, C. Simeone, C. Trombetta, V. Ficarra, M. Carini, A. Minervini
Journal: European Urology (2022)
Gender disparities in kidney surgery: A real-life snapshot for a large prospective, multicenter observational study (the RECORd2 Project)
Authors: A. Mari, A. Antonelli, A. Tafuri, R. Tellini, E. Brunocilla, U. Capitanio, F. Di Maida, P. Gontero, A.A. Grosso, S. Nardoni, V. Li Marzi, N. Longo, F. Montorsi, F. Porpiglia, A. Porreca, B. Rocco, C. Simeone, R. Schiavina, L. Schips, S. Siracusano, C. Terrone, V. Ficarra, M. Carini, A. Minervini
Journal: European Urology (2022)
Composite Superelastic Aerogel Scaffolds Containing Flexible SiO<sub>2</sub> Nanofibers Promote Bone Regeneration
Authors: Mingyue Liu, Muhammad Shafiq, Binbin Sun, Jinglei Wu, Wei Wang, Mohamed EL‐Newehy, Hany EL‐Hamshary, Yosry Morsi, Onaza Ali, Atta ur Rehman Khan, Xiumei Mo
Journal: Advanced Healthcare Materials (2022)

Repairing irregular-shaped bone defects poses enormous challenges. Scaffolds that can fully fit the defect site and simultaneously induce osteogenesis and angiogenesis hold great promise for bone defect healing. This study aimed to produce superelastic organic/inorganic composite aerogel scaffolds by blending silica nanofibers (SiO2 ) and poly (lactic acid)/gelatin (PLA/gel) nanofibers; the content of SiO2 nanofibers is varied from 0-60 wt% (e.g., PLA/gel, PLA/gel/SiO2 -L, PLA/gel/SiO2 -M, and PLA/gel/SiO2 -H for 0%, 20%, 40%, and 60% of SiO2 nanofibers, respectively) to produce a range of scaffolds. The PLA/gel/SiO2 -M scaffold has excellent elasticity and good mechanical properties. In vitro experiments demonstrate that the silicon ions released from PLA/gel/SiO2 -M scaffolds promote the differentiation of rat bone marrow-derived mesenchymal stem cells into osteoblasts, enhancing alkaline phosphatase activity and bone-related genes expressions. The released silicon ions also promote the proliferation of human umbilical vein endothelial cells and the expression of vascular endothelial growth factors, thereby promoting angiogenesis. The assessment of these scaffolds in a calvarial defect model in rats shows good potential of PLA/gel/SiO2 -M to induce bone regeneration as well as promote osteogenesis and angiogenesis. Overall, these organic/inorganic composite scaffolds have good biological activity, which may have broad applications for tissue engineering.
The utility of liquid biopsies for management of stage IV non-small cell lung cancer (NSCLC) in an academic community medical center.
Authors: Alisha Paro Maity, Mounika Gangireddy, Scott K. Dessain, Tracey L. Evans
Journal: Journal of Clinical Oncology (2022)

e20577 Background: The management of stage 4 non-squamous non-small cell lung cancer (NSCLC) relies heavily on the use of tumor genotyping that allows for the preferential use of targeted therapies as first-line treatment to eligible patients. Recently, the “liquid biopsy”, a non-invasive genomic analysis of circulating tumor DNA, has been deemed a suitable complementary method to identify actionable mutations and guide therapy in NSCLC patients. At our community-based academic medical system in suburban Philadelphia, liquid biopsies began to be used more regularly for these patients in 2018. All patients in the study received tissue biopsies with molecular testing. Our study compared patients who also underwent liquid biopsy with patients who did not, in order to determine whether performance of this biopsy affected their treatment. Methods: This retrospective cohort study used a bank of Main Line Health patients diagnosed with Stage 4 non-squamous NSCLC from 2014-2020. Chart review was used to extract variables from these patients regarding dates of tissue biopsies and treatments, information on liquid biopsies, and demographic information. The primary objective was to compare the rate of detection of actionable mutations in the liquid biopsy vs. non-liquid biopsy cohorts. A secondary objective was to assess the time interval between the identification of a potential lung cancer by imaging and the initiation of first line therapy. Results: 152 patients met inclusion criteria and of these 68 patients underwent liquid biopsy testing and 84 patients did not. Of the 68 patients who underwent liquid biopsy testing, 34 patients (50% patients) did not have sufficient tissue on their tissue biopsy for a molecular diagnosis. Of these 34 patients, 15 patients (44%) had an actionable mutation detected with liquid biopsy. Thus, 28 patients (41%) of the liquid biopsy group had actionable mutations detected. In comparison, only 18 patients (21%) in the cohort without liquid biopsy testing had actionable mutations detected. The initiation of first line treatment occurred sooner for the group undergoing liquid biopsies, an average of 48.3 days (median 40.5 days, range 13-317) compared to 72.7 days (median 50.5 days, range 14-534), p = 0.012 by two-tailed T-test. Conclusions: In our community academic medical center, patients with stage IV non-squamous, NSCLC who underwent a liquid biopsy as part of their initial diagnostic workup had a higher rate of detection of actionable mutations and initiated first line therapy sooner than patients who received only tissue-based molecular diagnostic testing.
MEDB-75. Treatment-induced pulmonary toxicity in patients with medulloblastoma: a retrospective analysis on 2 Italian institutions’ cohorts
Authors: Veronica Biassoni, Alessandra Busia, Francesco Barretta, Lorenza Gandola, Sabina Vennarini, Silvia Meroni, Angela Mastronuzzi, Giada Del Baldo, Silvia Chiesa, Emanuele Pignoli, Monica Terenziani, Emilia Pecori, Elisabetta Schiavello, Maura Massimino
Journal: Neuro-Oncology (2022)

Abstract BACKGROUND: Incidence of iatrogenic pulmonary toxicity is around 20%. Apart from bleomycin fibrosis, the role of lomustine, HD-thiotepa, autologous stem-cells transplantation(APBSCT) and their synergy with craniospinal irradiation(CSI) are unclear. To elucidate their role in lung-function impairment, we retrospectively evaluated 39 medulloblastoma patients treated at INT-Milan and OPBG-Rome. METHODS: 39 patients (17 females, median RT age 8 years) treated for localized(29) or metastatic(10) medulloblastoma in 2000-2020 and with spirometric assessment, were considered. Treatment included: SIOP-like-PNET IV(19), high-risk protocol(19), infant protocol without RT(1). CSI doses were: 23.4Gy(20), 31.2Gy(8), 36Gy(6) and 39Gy(4); 4 received protons and 34 photons(9 VMAT, 25 3D), 11 hyperfractionated-accelerated-RT; 33 had 6 median CCNU cycles; 6 APBSCT. RESULTS: Median follow-up: 98 months. All patients performed at least one spirometry at median 5 years after RT. Eight (20.6%) had mildly pathological spirometries, 8 Forced Vital Capacity (FVC%)&amp;lt;90%. RT age was not associated with FVC%/ PEF% (p=0.319 and 0.405). A lower Peak Expiratory Flow(PEF%) was marginally associated to APBSCT group (p=0.062) with FVC%(≤90% vs &amp;gt;90%) similar but less significant(p=0.163). Median FVC%/PEF% were higher in the CCNU-group without reaching significance (p=0.436 and 0.062): this was a standard-risk group not receiving APBSCT nor higher RT doses. Even though the lung volume encompassed by 5-10 Gy isodoses was greater in VMATvs3D RT(p&amp;lt;0.001 and p=0.015), there were no significant differences in ventilatory parameters. FVC%/PEF% were negatively associated to CSI dose. Since no relevant lung volume is involved in high doses, a multifactorial etiology could be speculated. CONCLUSIONS: Preliminary data show no significant FVC%/PEF% reduction. Small sample size and differences in spirometry techniques impose larger cohorts accrual to elucidate potential treatment-induced pulmonary impairment in the pediatric population thus validating the use of spirometry during treatment/follow-up.
Radiation therapy after radical prostatectomy is associated with higher other-cause mortality
Authors: C. Würnschimmel, M. Wenzel, F. Chierigo, R.S. Flammia, B. Horlemann, Z. Tian, F. Saad, A. Briganti, S.F. Shariat, N. Suardi, F.K.H. Chun, D. Tilki, M. Graefen, P.I. Karakiewicz
Journal: European Urology (2022)
Disclosing Alzheimer Disease Biomarker Results to Research Participants
Authors: Joshua D. Grill, Jason Karlawish
Journal: JAMA Neurology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study
Authors: Nghia H. Nguyen, Jiyu Luo, Paulina Paul, Jihoon Kim, Gaurav Syal, Christina Ha, Vivek Rudrapatna, Sunhee Park, Nimisha Parekh, Kai Zheng, Jenny S. Sauk, Berkeley Limketkai, Phillip Fleshner, Samuel Eisenstein, Sonia Ramamoorthy, Gil Melmed, Parambir S. Dulai, Brigid S. Boland, Uma Mahadevan, William J. Sandborn, Lucila Ohno-Machado, Dermot McGovern, Siddharth Singh
Journal: Clinical Gastroenterology and Hepatology (2022)
Candidate therapeutic agents in a newly established triple wild‐type mucosal melanoma cell line
Authors: Chaoji Shi, Ziyue Gu, Shengming Xu, Houyu Ju, Yunteng Wu, Yong Han, Jiayi Li, Chuwen Li, Jing Wu, Lizhen Wang, Jiang Li, Guoyu Zhou, Weimin Ye, Guoxin Ren, Zhiyuan Zhang, Rong Zhou
Journal: Cancer Communications (2022)

Mucosal melanoma has characteristically distinct genetic features and typically poor prognosis. The lack of representative mucosal melanoma models, especially cell lines, has hindered translational research on this melanoma subtype. In this study, we aimed to establish and provide the biological properties, genomic features and the pharmacological profiles of a mucosal melanoma cell line that would contribute to the understanding and treatment optimization of molecularly-defined mucosal melanoma subtype.
Indirect assessment of tumor-infiltrating lymphocyte activity in serum for predicting outcome in patients with glioblastoma treated with immunotherapy in the recurrent setting.
Authors: Christina Jensen, Simone Bendix Maarup, Hans Skovgaard Poulsen, Benedikte Hasselbalch, Morten A. Karsdal, Inge Marie Svane, Ulrik Niels Lassen, Nicholas Willumsen
Journal: Journal of Clinical Oncology (2022)

2059 Background: Glioblastoma (GBM) is an aggressive brain tumor and despite efforts in developing new effective therapies, patient survival remains low. There is increasing interest in using immune checkpoint inhibitors (ICIs) for GBM, however the immunosuppressive (cold tumor) characteristics of GBM limit the efficacy of ICIs. Consequently, there is a need to identify patients with active tumor-infiltrating lymphocytes (hot tumor). Several studies have shown that brain extracellular matrix such as type IV collagen has a dynamic composition with protease-induced alterations. In this study, we evaluated the clinical utility of a non-invasive biomarker of granzyme B degraded type IV collagen (C4G) reflecting tumor-infiltrating lymphocyte activity and of matrix metalloproteinase (MMP) degraded type IV collagen (C4M) in GBM patients treated with nivolumab (anti-PD-1) and bevacizumab (anti-VEGF) in the recurrent setting. Methods: C4G and C4M were measured in serum from 22 controls and 39 GBM patients previously treated with surgery, radiotherapy and chemotherapy in the primary setting. After GBM recurrence, 18 patients underwent salvage resection (arm A) however 21 patients had no possibility for resection (arm B). All patients were treated with nivolumab and bevacizumab (NCT03890952 phase II study). Baseline GBM samples were taken before the second-line treatment. The association between C4G levels and outcome was evaluated by Cox regression analysis for overall survival (OS) and odds ratio (OR) calculations for complete response (CR) rate after dichotomizing patients into low vs high levels of C4G (median cutpoint). Results: C4G (p = 0.004), but not C4M (p = 0.166), was significantly elevated in serum from GBM patients compared to controls. Moreover, patients with high C4G levels had a significantly increased likelihood of experiencing CR (OR=6.68, p&lt;0.0001). Furthermore, patients with high C4G experienced improved OS compared to low C4G (HR=0.39), and this remained significant after adjusting for other significant risk factors (treatment arm and MGMT methylation) by multivariate analysis (HR=0.44) (table). Conclusions: A non-invasive biomarker reflecting tumor-infiltrating lymphocyte activity (C4G) has the potential to identify GBM patients responding to nivolumab and bevacizumab in the recurrent setting. In the future, this may provide a non-invasive biomarker tool for stratifying patients with GBM for ICI trials. Clinical trial information: NCT03890952. [Table: see text]
Bladder cryo-injury induced detrusor underactivity rat model: Early effects of adipose-derived stem cell sheet and their differentiation
Authors: S. Teraoka, M. Honda, K. Makishima, R. Shimizu, P. Tsounapi, T. Yumioka, N. Yamaguchi, B. Kawamoto, H. Iwamoto, P. Li, S. Morizane, K. Hikita, I. Hisatome, A. Takenaka
Journal: European Urology (2022)
A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology
Authors: F. Michel, F. Cancrini, G. Cancel-Tassin, X. Gamé, E. Huyghe, A. Rock, G. Léon, A. Uzan, F-R. Desfemmes, B. Peyronnet, J. Fallot, P. Léon, E. Rolland, M-A. Perrouin-Verbe, J. Wodey, G. Capon, G. Karsenty, M. Rouprêt, O. Cussenot, H. Alshehhi, E. Comperat, V. Phé
Journal: European Urology (2022)
Use of Merlin Assay to identify patients with a low-risk for SN metastasis in a prospective multicenter Dutch study of a primary melanoma gene-signature (CP-GEP model) to predict sentinel node status during COVID-19.
Authors: Robert Stassen, Evalyn Mulder, Antoine Veringa, Antien Mooyaart, Jvalini Dwarkasing, Dennie Tempel, Jos A. van der Hage, Sandra Lendfers, Maureen J.B. Aarts, Cornelis Verhoef, Anne Brecht Francken, Dirk J. Grunhagen
Journal: Journal of Clinical Oncology (2022)

9571 Background: Approximately 70%-85% of patients who undergo sentinel lymph node biopsy (SLNb) show no nodal metastasis in the sentinel node (SN). The clinicopathological and gene expression profile (CP-GEP) model ( Merlin Assay) was developed and validated to identify patients that may forgo the SLNb surgery due to their low risk for for nodal metastasis This study was initiated during the first wave of Covid-19 pandemic to allow for surgical triage on SLNb and evaluate the implementation of the Merlin assay in clinical practice. Methods: This study was conducted in four designated melanoma centers in the Netherlands. Patients (age &gt; 18y) with newly diagnosed melanoma of the skin, eligible to undergo SLNb were screened for study inclusion. Main exclusion criteria was prior history of primary melanoma ( &gt; T1b) in the past 5 years. After enrollment, tissue sections of the primary melanoma were centrally reviewed at the Erasmus MC Cancer Institute to determine Breslow thickness at primary diagnosis. FFPE tumor tissue was dispatched for molecular analysis of eight target genes known to play a role in cancer development. In combination with age, Breslow thickness, and GEP outcome, risk of having nodal metastasis was calculated. Results were binary presented as 'CP-GEP low risk' and 'CP-GEP high risk'. SLNb status was used as gold standard for comparison. Results: A total of 177 patients were analyzed using the CP-GEP model. Median age was 64 years (IQR 52-73) Median Breslow thickness was 1.4mm (IQR 1.0-2.4). Of all patients 28.2% was diagnosed with T1, 40.7% with T2 and 20.9% with T3 melanoma. Corresponding positivity rate was 7%, 14% and 29% respectively. A total of 24 out of 177 patients had a positive SLNb. Median turn-around time from inclusion to CP-GEP result was 15 days. Overall 37.1.% of patients had a CP-GEP low risk profile. The CP-GEP model had a NPV of 94.6%. Conclusions: This is the first prospective multicenter implementation study for the Merlin assay. Results are in line with previous validation studies. The CP-GEP model could accurately identify patients at low risk for SN metastasis. Implementation in clinical practice is feasible based on current turn-around time. In the future, using the Merlin assay to deselect patients for SLNB may allow for a reduction of surgery in patients with melanoma.